Policy / Pricing FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ pharminent June 19, 2026
Policy / Pricing How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan Market pharminent June 11, 2026
Policy / Pricing Medicare Part D Enrollment, Premiums, and Cost Sharing in 2026 pharminent June 11, 2026
Policy / Pricing The next FDA commissioner must be a champion for gene therapies pharminent June 5, 2026
Policy / Pricing Stakeholders want Makary’s voucher program paused, call for FDA independence pharminent June 5, 2026
Policy / Pricing The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs pharminent June 2, 2026
Policy / Pricing Hospital Prices Have Risen Much Faster for Private Insurance Than Medicare Since 2019 pharminent May 18, 2026
Policy / Pricing FDA’s leadership void leaves biotech with renewed ‘uncertainty’ pharminent May 13, 2026
Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged pharminent May 13, 2026
Policy / Pricing Makary resigns, with Diamantas named as acting FDA commissioner pharminent May 12, 2026
Policy / Pricing 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) pharminent May 12, 2026
Policy / Pricing What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge pharminent May 11, 2026
Policy / Pricing FDA Advances Drug Repurposing to Address Unmet Medical Needs pharminent May 11, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs) pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Qualified Medicare Beneficiaries (QMBs) pharminent April 30, 2026
Policy / Pricing Eligibility for Medicare Savings Programs for Qualifying Individuals (QIs) pharminent April 30, 2026
Policy / Pricing Average Drug Fills and Average Gross Drug Costs Per Medicare Part D Enrollee pharminent April 30, 2026
Policy / Pricing Regeneron cuts White House pricing deal, offers new gene therapy for free pharminent April 24, 2026
Policy / Pricing CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices pharminent April 23, 2026
Policy / Pricing Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care pharminent April 23, 2026
Policy / Pricing FDA Releases Congressional Justification for FY 2027 Budget, Including Proposal Regarding Interchangeability of Biosimilars pharminent April 22, 2026
Policy / Pricing Trump’s psychedelics push a mixed blessing for neuropsychiatric companies, patients pharminent April 22, 2026
Policy / Pricing Medicare obesity drug pilot extended after insurer pushback pharminent April 22, 2026
Policy / Pricing FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development pharminent April 20, 2026
